MINI LONG - ZEALAND PHARMA Share Price

Certificat

MINI L ZEAL AVA

GB00BSJJDS21

Market Closed - Nasdaq Stockholm 07:44:03 29/05/2024 pm IST
33.78 ^SEK	+0.27%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ZEALAND PHARMA A/S

Latest news about ZEALAND PHARMA A/S

Zealand Pharma, Boehringer Ingelheim Weight Loss Compound Hits Midstage Endpoints for Liver Fibrosis	07/06	MT
Zealand Pharma A/S : announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	07/06	PU
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	07/06	GL
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL	06/06	GL

More news

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	CALL
Underlying	ZEALAND PHARMA A/S
Issuer	Morgan Stanley
	MINI L ZEAL AVA
ISIN	GB00BSJJDS21
Date issued	18/04/2024
Strike	399.5 kr
Maturity	Unlimited
Parity	10 : 1
Emission price	- kr
Emission volume	N/A
Settlement	cash
Currency	SEK

Technical Indicators

Highest since issue	35.89 kr
Lowest since issue	33.69 kr
Spread	0.82 kr
Spread %	2.08%

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Sector

More about the company